Paper
10 February 2011 Study of photosensitizers pharmacokinetics in mouse tumor model by transillumination fluorescence imaging in vivo
Author Affiliations +
Abstract
In this work we demonstrate an efficiency of transillumination fluorescence imaging for intravital study of photosensitizers pharmacokinetics in tumor-bearing mice. Experiments were performed on CBA mice with subcutaneously transplanted cervical carcinoma. Photosensitizer fotoditazin was used in the therapeutic dose of 10 mg/kg, i.v. Measuring the fluorescence in the whole tumors at different times after injection of photosensitizer, we obtained in vivo data about the drug accumulation and elimination. It was found in vivo that the period of maximum uptake of the photosensitizer in the mouse tumor is from 1 to 8 h post-injection, and its concentration in the tumor tissue at this time is about 2 μg/g. An accumulation of the photosensitizer in the tumor was confirmed by standard methods ex vivo. Noninvasive assessment of pharmacokinetics by transillumination imaging setup provides an opportunity for rapid and cost-effective studies of newly developed photosensitizers.
© (2011) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Marina V. Shirmanova, Irina V. Balalaeva, Marina A. Sirotkina, Natalya Yu. Lekanova, Ilya V. Turchin, and Elena V. Zagainova "Study of photosensitizers pharmacokinetics in mouse tumor model by transillumination fluorescence imaging in vivo", Proc. SPIE 7886, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XX, 78860U (10 February 2011); https://doi.org/10.1117/12.873870
Lens.org Logo
CITATIONS
Cited by 2 scholarly publications.
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Luminescence

In vivo imaging

Tissues

Tissue optics

Tumor growth modeling

Skin

Back to Top